Peer-reviewed science, clinical evidence, and policy analysis to help Georgia patients, caregivers, and healthcare providers make informed decisions about medical cannabis.
GMCS is committed to evidence-based advocacy and education. We curate and summarize research from peer-reviewed journals, federal agencies, and leading academic institutions so that patients, caregivers, and providers have access to accurate, current information — without having to wade through the full scientific literature themselves. Our research resources are updated regularly as new evidence emerges.
Clinical Research
Peer-reviewed studies on the efficacy and safety of medical cannabis for specific conditions, including chronic pain, epilepsy, PTSD, multiple sclerosis, and other qualifying conditions under Georgia law.
Policy & Law
Analysis of Georgia's medical cannabis statutes, regulatory framework, and legislative history — including SB 219, SB 220, and federal rescheduling to Schedule III (April 22, 2026).
Pharmacology & Safety
Research on cannabinoid pharmacology, drug interactions, dosing considerations, contraindications, and safe use guidance for patients and providers.
Public Health
Population-level research on medical cannabis access, health equity, patient outcomes, and the public health implications of state medical cannabis programs.
Chronic pain is the most common qualifying condition in state medical cannabis programs. Research consistently shows cannabinoids — particularly CBD and THC combinations — can reduce pain intensity and improve quality of life for patients with neuropathic, inflammatory, and musculoskeletal pain.
CBD-based treatments have the strongest evidence base in cannabis medicine, with FDA-approved Epidiolex demonstrating significant seizure reduction in Dravet syndrome and Lennox-Gastaut syndrome. Georgia's registry includes intractable seizure disorders as a qualifying condition.
Emerging research supports the use of medical cannabis for PTSD symptom management, particularly for sleep disturbance, nightmares, and hyperarousal. PTSD is a qualifying condition under Georgia law.
On April 22, 2026, cannabis was rescheduled from Schedule I to Schedule III under the federal Controlled Substances Act. This landmark change has significant implications for research access, banking, taxation, and the future of state medical cannabis programs.
Signed May 12, 2026, SB 220 expanded Georgia's medical cannabis program — adding qualifying conditions, authorizing new product forms, extending card validity, and allowing digital card acceptance. GMCS has published a full analysis of the law's provisions.
Cannabis interacts with a range of commonly prescribed medications through the cytochrome P450 enzyme system. Providers and patients should review potential interactions — particularly with anticoagulants, antiepileptics, and immunosuppressants — before initiating medical cannabis.
GMCS members have access to the full research library, including curated article summaries, provider-facing clinical briefs, and policy analysis documents. Patient resources — including plain-language research summaries — are available to all visitors.
Disclaimer: Research summaries provided by GMCS are for educational purposes only and do not constitute medical advice. GMCS does not endorse specific products, brands, or treatment protocols. Patients should consult their certifying physician before making any changes to their care plan.
GMCS publishes research updates, policy analysis, and evidence summaries for members and the public. Join GMCS or sign up for our newsletter to receive updates.
